Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Curia, formerly AMRI, a leading contract research, development and manufacturing organization, today announced it has entered into a definitive agreement to acquire LakePharma Inc., a privately held biologics drug discovery, clinical research, development and manufacturing organization with operations in California, Massachusetts, and Texas.

Established in 2009 in the Bay Area, LakePharma applies its range of technology platforms to advance projects from discovery to development to manufacturing, namely cell-line development, bioexpression systems and viral vector production systems. Almost a quarter of its employees hold Ph.D.s, bringing expertise in all major biologics segments: mammalian, microbial, plasmid DNA, mRNA, monoclonal antibodies, and viral vector, including cell and gene therapy. LakePharma has contributed to the development of more than 200 therapeutic or diagnostic products and served more than 1,500 customers, including 22 of the top 25 global biopharmaceutical companies.

After the transaction close, the combined company will provide deep expertise in both large and small molecules from drug discovery through drug substance manufacturing, sterile injectable formulation and fill-finish production.

LakePharma’s six facilities and 235 employees will join with Curia’s 21 sites and more than 3,100 employees to offer clients an end-to-end partnership in drug discovery, formulation and process development as well as drug substance and drug product clinical and commercial manufacturing. Curia recently announced it has also signed a definitive agreement to acquire Integrity Bio, a privately held formulation and fill-finish organization headquartered in Camarillo, California.

LakePharma will expand our integrated approach to provide biotech and pharmaceutical companies with small and large molecule research, development and manufacturing solutions.

Funding and innovation in the biotech sector remains strong. Our combined capabilities will enable us to partner with our customers by seamlessly providing LakePharma’s multi-modality innovation and speed along with fill-finish solutions from Curia. Our agreements with LakePharma and Integrity Bio demonstrate our commitment to expanding and deepening our biologics capabilities to help our customers advance from curiosity to cure.”

Curia Chairman & CEO John Ratliff

Hua Tu, Ph.D., founder and CEO of LakePharma, said: “LakePharma is delighted to join the Curia family. Over the last 12 years, we have built a strong brand as ‘The Biologics Company,’ a talented and dedicated employee team, and a loyal and supportive client base. We are excited to join Curia’s global network, including commercial manufacturing capabilities, in delivering end-to-end integrated biologics solutions to our pharma and biotech clients.”

RBC Capital Markets, LLC is serving as exclusive financial adviser to Curia and Nelson Mullins Riley & Scarborough LLP is serving as Curia’s legal counsel. Goldman Sachs & Co. LLC is serving as financial adviser to LakePharma, and Fenwick & West LLP is serving as LakePharma’s legal counsel. The transaction, which is subject to standard and customary closing conditions, is expected to close in the third quarter. Terms of the agreement have not been disclosed.

About Curia

Curia, formerly AMRI, is a leading contract research, development and manufacturing organization providing products and services from R&D through commercial manufacturing to pharmaceutical and biopharmaceutical customers. Curia’s 3,100 employees at 21 locations across the U.S., Europe and Asia help its customers advance from curiosity to cure. Learn more at CuriaGlobal.com.

About LakePharma

LakePharma is a U.S.-based biologics CRDMO with operations in California, Texas, and Massachusetts. This biotech company specializes in the production and evaluation of DNA vectors, viral vectors, cell lines, proteins, antibodies, mRNA and conjugates while providing integrated solutions bridging discovery, engineering, development, and GMP manufacturing. LakePharma has contributed to the development of 200+ therapeutic or diagnostic products and strives to develop hundreds more. Learn more at www.LakePharma.com.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Curia. (2021, July 14). Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics. News-Medical. Retrieved on September 20, 2021 from https://www.news-medical.net/news/20210714/Curia-to-Acquire-US-based-LakePharma-Expanding-End-to-End-RD-Capabilities-and-Scale-for-Biologics.aspx.

  • MLA

    Curia. "Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics". News-Medical. 20 September 2021. <https://www.news-medical.net/news/20210714/Curia-to-Acquire-US-based-LakePharma-Expanding-End-to-End-RD-Capabilities-and-Scale-for-Biologics.aspx>.

  • Chicago

    Curia. "Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics". News-Medical. https://www.news-medical.net/news/20210714/Curia-to-Acquire-US-based-LakePharma-Expanding-End-to-End-RD-Capabilities-and-Scale-for-Biologics.aspx. (accessed September 20, 2021).

  • Harvard

    Curia. 2021. Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics. News-Medical, viewed 20 September 2021, https://www.news-medical.net/news/20210714/Curia-to-Acquire-US-based-LakePharma-Expanding-End-to-End-RD-Capabilities-and-Scale-for-Biologics.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.